A 3-year-old girl from rural Bihar presents with her mother complaining of difficulty seeing at night for the past 2 weeks. On examination, the child has conjunctival xerosis with Bitot's spots bilaterally. Visual acuity is 6/9 in both eyes. There is no corneal involvement. The child's diet consists mainly of rice and lentils with minimal vegetables or animal products. What is the most appropriate immediate management?

Explanation

## Clinical Presentation Analysis This child presents with **night blindness (nyctalopia)** and **conjunctival xerosis with Bitot's spots**, which are hallmark signs of **vitamin A deficiency (VAD) Stage XN and X1** respectively. ### Xerophthalmia Staging (WHO Classification) | Stage | Clinical Finding | Reversibility | |-------|------------------|----------------| | **XN** | Night blindness | Fully reversible | | **X1A** | Conjunctival xerosis | Fully reversible | | **X1B** | Bitot's spots | Fully reversible | | **X2** | Corneal xerosis | Fully reversible | | **X3A** | Corneal ulceration/scarring < 1/3 | Reversible | | **X3B** | Corneal scarring > 1/3 | Irreversible (blindness) | | **XS** | Corneal scar | Irreversible | ### Recommended Dosing for Vitamin A Deficiency **Key Point:** The WHO/UNICEF protocol for **Stage X1 (conjunctival xerosis with Bitot's spots)** in children aged 1–8 years is: - **200,000 IU orally on Day 1** - **200,000 IU orally on Day 2** - **200,000 IU orally 2 weeks later** (to replenish liver stores) **High-Yield:** This dosing achieves rapid restoration of retinol-binding protein and visual function while avoiding toxicity. The two-week interval dose is critical because it addresses hepatic stores depletion. ### Why This Stage Requires Urgent High-Dose Therapy **Clinical Pearl:** Although this child has no corneal involvement yet (Stage X1, not X2 or X3), the presence of **Bitot's spots indicates significant systemic VAD**. Without intervention, progression to corneal xerosis (X2) and ulceration (X3) occurs within days to weeks, leading to irreversible scarring and blindness. **Mnemonic: "2-2-2 Rule"** — 200,000 IU, Day 2, and 2 weeks later (the three "2"s of WHO VAD management). ### Why Other Options Are Inadequate - **Topical lubricants alone:** Symptomatic relief only; does not address systemic VAD or prevent progression to corneal scarring. - **Intramuscular dosing:** Not first-line in children with intact GI absorption; oral is preferred and equally effective. - **Low-dose daily supplementation (10,000 IU):** Insufficient to replenish depleted liver stores; used for maintenance/prevention, not acute deficiency. **Warning:** Delaying high-dose therapy in Stage X1 risks rapid progression to irreversible blindness within 1–2 weeks.